论文部分内容阅读
[目的]评价乳腺癌化疗紫杉类药物敏感性相关基因的研究状况,并对未来研究方向进行预测。[方法]选用Embase、Medline/Pubmed、BIOSIS Preview数据库为文献来源,对2001～2010年期间与乳腺癌化疗紫杉类药物敏感性相关基因的文献进行计量学分析。[结果]相关文献93篇,文献中涉及429个基因。生物信息学分析说明所涉及的基因及其产物处于相互联系的复杂网络之中,同时为关键基因和瓶颈基因主要有PLK1、CCND1、ESR1、FEN1、CDKN1A、CCNA2、TP53、SRC、EGFR、PIK3CA、MDM2、CCNB1、VEGFA、TOP2A、BRCA1、Bcl-2、FOXM1、EP300、CTNNB1、BIRC5等。[结论]乳腺癌化疗紫杉类药物敏感性相关基因的研究可能在未来研究中更受关注,我们预测的关键基因可能成为未来研究的热点。
[Objective] To evaluate the research status of chemosensitivity related genes of chemotherapy for taxane in breast cancer and to predict the future research direction. [Methods] Embase, Medline / Pubmed and BIOSIS Preview databases were selected as the source of the literature, and the etiological data of the genes related to chemotherapy-induced taxanes in breast cancer from 2001 to 2010 were analyzed. [Results] There were 93 related literatures, involving 429 genes in the literature. Bioinformatics analysis shows that the involved genes and their products are in a complex network of interconnectedness. The key genes and bottleneck genes are PLK1, CCND1, ESR1, FEN1, CDKN1A, CCNA2, TP53, SRC, EGFR, PIK3CA, MDM2, CCNB1, VEGFA, TOP2A, BRCA1, Bcl-2, FOXM1, EP300, CTNNB1, BIRC5 and the like. [Conclusion] The research on chemosensitivity related gene of taxanes in breast cancer chemotherapy may be more concerned in the future research. The key genes we predicted may become hot topics in the future.